Lucentis definition

Lucentis means the antibody product with the generic name ranibizumab, whether sold under the name Lucentis or any other name.
View Source
Lucentis means GENENTECH’s product known as LUCENTIS®, which binds to the vascular endothelial growth factor Antigen and is a Licensed Product, as well as any and all pharmaceutical formulations and packaged forms of that product.” (b) Section 3.2 of the LUCENTIS License Agreement is hereby amended by adding the following to the end thereof: “Notwithstanding the foregoing, effective upon the date of payment by GENENTECH to XOMA of the Royalty Repurchase Fee provided for in Section 3.6, GENENTECH’s obligation under this Section 3.2 to pay any royalty on Net Sales of LUCENTIS for any period either in the past or in the future is extinguished, and XOMA specifically agrees that upon the receipt of the Royalty Repurchase Fee, XOMA shall have no right to seek any additional royalties for any Net Sales of LUCENTIS that may have occurred at any time in the past or that may occur at any time in the future.” (c) Article 3 of the LUCENTIS License Agreement is hereby amended by adding the following to the end thereof:
View Source
Lucentis means the antibody product with the generic name ranibizumab, whether sold under the name Lucentis or any other name. 15. The following Section 1.19 is added to the PLMA:
View Source

Examples of Lucentis in a sentence

  • Genentech also shall determine the amount of royalties it paid to PDL for sales or other transfers of Lucentis in the United States for the period from and including July 1, 2013 to and including September 30, 2013, and deduct such amount from any additional royalties owed to PDL.

  • Lucentis is the only FDA-approved therapy for wet AMD, which in clinical trials showed an improvement in vision of three lines or more on the study eye chart in up to 41 percent of patients at two years.

  • The remaining four approved reference biologic anti-VEGF drugs for the treatment of nAMD generated, based on publicly available SEC filings and publicly available regulatory documents reporting 2023 global net revenues for Eylea, Vabysmo, Lucentis and Eylea HD, an estimated worldwide revenue of $14 billion in 2023 with aflibercept alone generating worldwide sales of approximately $9 billion.

  • More than three million people in the United States are currently impacted by significant visual impairment or blindness resulting from these retinal diseases, and the branded market for therapeutics used to treat them was estimated, based on publicly available SEC filings and publicly available regulatory documents reporting 2023 global net revenues for Eylea, Vabysmo, Lucentis and Eylea HD, to be $14 billion worldwide in 2023.

  • Patients receiving the combination of Fovista (1.5 mg) and Lucentis gained a mean of 10.6 letters of vision on the ETDRS standardized chart at 24 weeks, compared to 6.5 letters for patients receiving Lucentis monotherapy (p=0.019), representing a 62% additional benefit.

  • With respect to Lucentis, Genentech will owe no royalties on U.S. sales occurring after June 30, 2013, and will pay a royalty of 2.125 percent on all ex-U.S. sales occurring on or before December 28, 2014.

  • Lucentis responsible for and will defend, indemnify, and hold harmless the Buyer, and the Buyer’s successors-in-interest, assignees, affiliates, directors, officers, and employees against all losses, claims, expenses, or damages which may result from accident, injury, damage, or death due to ▇▇▇▇▇▇’s breach of the Limited Warranty.

  • Lucentis was discovered at Genentech and is being developed by Genentech and the Novartis Ophthalmics Business Unit for diseases or disorders of the eye.

  • The agreement, which includes Lucentis and potentially other products, addresses a wide range of ophthalmic diseases and leverages our expertise and technology platforms in ophthalmology, employs our proprietary biodegradable microparticles drug delivery system from SurModics Pharmaceuticals, and will utilize our new world-class cGMP manufacturing facility in Birmingham, Alabama.” ▇▇▇▇▇▇▇ added, “This agreement has the opportunity to provide both near- and long-term value to SurModics’ shareholders.

  • Novartis shall provide the Lucentis product free of charge for use in the Novartis Territory in the Existing Fovista Clinical Program from and after the Effective Date and in future Phase II Clinical Studies and Phase III Clinical Studies (including phase IIIb clinical studies) involving Fovista and Lucentis that may be conducted in the Novartis Territory under this Agreement.

Related to Lucentis

  • Novartis shall have the meaning set forth in the Preamble.

  • Pfizer means Pfizer Inc.

  • DSM means the most current edition of the Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Association.

  • Intel means Intel Corporation, a Delaware corporation.

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.